Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockMiser who wrote (590)	4/22/1999 7:19:00 PM
From: StockMiser	Read Replies (3) of 2344

A little insight into the stem cell study off the Yahoo boards... Re: in vitro studies by: ThriftyDrifty 3144 of 3148 As someone already has pointed out, the abstract published in the immunotherapy journal by the Fred Hutchinson doctors address in vitro activity associated with Theratope. While the data is interesting and suggests that Theratope stimulates an immune response, the clinical activity of Theratope (as opposed to any in vitro activity) is what is significant. Knowing the extent to which Theratope actually leads to disease regression and/or extended disease-free survival (or cure) is what is key. The ASCO presentation by the Fred Hutchinson doctors presumably will address the clinical data. I have no doubt that the ASCO news will be good. I know the Fred Hutchinson doctors spearheading this study; based on what they told me three months ago, they are very excited about the clinical results they've been seeing. --------- And a reply by Redplate ./.. Importance of in vitro by: redplate (44/M/Seattle) 3145 of 3148 The importance of the in vitro results actually relates to the patent positions for Theratope. One of the issued patents makes claims of treatment with carbohydrate vaccines to which there is a cellular immune response. Other patents realte to methods of synthesis etc, but this a treatment patent and is an important part of the supporting IP. The presentation at ASCO will not likely focus on much of the in vitro results, althought I am sure that induced antibody titers will be presented as the bridging studies were designed to show equivelent or better antibody responses with similar "antigenic functionality" of the vaccine. This is fairly standard stuff for a scale up study to show the final product is equal or better in the field of vaccines. I also expect some data on patient outcomes, although it is very early to expect dramatic data on survival. But perhaps some Kaplan Mieir curves as has been done in the past could show a projection of results. It is not likely that a median survival is as yet acheived (I hope not). I have read the release and this is pretty good language for such a conservative group. Confidence is high in my camp.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next